, Tracking Stock Market Picks
Enter Symbol:
Trius Therapeutics, Inc. (TSRX) [hlAlert]

up 144.26 %

Trius Therapeutics, Inc. (TSRX) rated Buy with price target $7 by WBB Securities

Posted on: Wednesday,  Aug 29, 2012  9:25 AM ET by WBB Securities

WBB Securities rated Buy Trius Therapeutics, Inc. (NASDAQ: TSRX) on 08/29/2012, when the stock price was $5.58. Since
then, Trius Therapeutics, Inc. has gained 144.27% as of 09/11/2014's recent price of $13.63.
If you would have followed this WBB Securities's recommendation on TSRX, you would have gained 144.26% of your investment in 743 days.

Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibiotics for life threatening infections. The Company is developing torezolid phosphate, an intraveneous (IV) and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections (ABSSSI), and subsequently for other indications. The Company initiated its Phase III clinical program for torezolid phosphate for the treatment of ABSSSI in August 2010. In addition, the Company is developing antibiotics for gram-negative infections using its discovery platform under two contracts: one funded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH) and the other funded by the Defense Threat Reduction Agency (DTRA), a part of the Department of Defense.

Research from WBB Securities provides investment professionals with up-to-date, in-depth, accurate and insightful reporting of companies that specialize in biotechnology, medical devices and healthcare. Our goal is to provide independent, straight-forward and up-to-date research so you can make educated decisions about your investments.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/29/2012 9:25 AM Buy
5.58 7.00
as of 12/31/2012
1 Week down  -4.78 %
1 Month down  -0.20 %
3 Months down  -18.01 %
1 YTD down  -14.33 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy